- Home
- BARK vs IMMP Comparison
BARK vs IMMP Comparison
Compare BARK & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BARK
- IMMP
- Stock Information
- Founded
- BARK 2011
- IMMP 1987
- Country
- BARK United States
- IMMP Australia
- Employees
- BARK N/A
- IMMP N/A
- Industry
- BARK Department/Specialty Retail Stores
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- BARK Consumer Discretionary
- IMMP Health Care
- Exchange
- BARK Nasdaq
- IMMP Nasdaq
- Market Cap
- BARK 244.9M
- IMMP 251.8M
- IPO Year
- BARK N/A
- IMMP N/A
- Fundamental
- Price
- BARK $0.81
- IMMP $1.60
- Analyst Decision
- BARK Strong Buy
- IMMP Buy
- Analyst Count
- BARK 3
- IMMP 1
- Target Price
- BARK $2.50
- IMMP $7.00
- AVG Volume (30 Days)
- BARK 2.3M
- IMMP 111.5K
- Earning Date
- BARK 08-06-2025
- IMMP 02-27-2025
- Dividend Yield
- BARK N/A
- IMMP N/A
- EPS Growth
- BARK N/A
- IMMP N/A
- EPS
- BARK N/A
- IMMP N/A
- Revenue
- BARK $484,182,000.00
- IMMP $3,019,249.00
- Revenue This Year
- BARK N/A
- IMMP $50.37
- Revenue Next Year
- BARK $9.47
- IMMP N/A
- P/E Ratio
- BARK N/A
- IMMP N/A
- Revenue Growth
- BARK N/A
- IMMP 24.11
- 52 Week Low
- BARK $0.77
- IMMP $1.32
- 52 Week High
- BARK $2.56
- IMMP $2.80
- Technical
- Relative Strength Index (RSI)
- BARK 29.15
- IMMP 38.39
- Support Level
- BARK $0.77
- IMMP $1.51
- Resistance Level
- BARK $0.91
- IMMP $1.92
- Average True Range (ATR)
- BARK 0.07
- IMMP 0.08
- MACD
- BARK -0.01
- IMMP -0.03
- Stochastic Oscillator
- BARK 6.82
- IMMP 21.95
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.